MGNX — MACROGENICS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1125345 ·
Last close
$2.05
Market Cap
$131.01M
52W High
$5.08
52W Low
$1.32
ADV30
919,400
Next earnings
2026-11-12
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 18,667,000 — -20,303,000 -20,076,000 318,685,000 49,029,000 293,534,000
Jun 2026 32,832,000 — -13,852,000 19,515,000 345,409,000 113,907,000 302,536,000
Mar 2026 20,775,000 11,245,000 -33,439,000 -36,774,000 217,873,000 66,517,000 196,675,000
Dec 2025 41,227,000 31,112,000 -12,097,000 -14,155,000 256,846,000 57,217,000 201,255,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,724,000
Investing CF
$-13,078,000
Financing CF
$60,023,000
CapEx
$-1,820,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.57
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,261,597,000
Inventory
$9,498,000
Receivables
$144,173,000
ST Investments
$59,398,000
EBIT TTM
$-87,627,000
Pretax Income TTM
$-104,526,000
Interest Exp TTM
$16,899,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$140,804,992
EBITDA
$-64,452,000
Free Cash Flow
$99,187,000
Enterprise Value
$-112,218,320
Total Cash
$287,680,000
Total Debt
$34,862,000
Shares Out
63,908,946
Trailing EPS
$-2.30
Book Value
$0.39
ROE
-284.5%
ROA
-14.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 149,500,000 -72,841,000 -74,620,000 256,846,000 201,255,000 55,591,000 -81,040,000
Dec 2024 149,962,000 -110,578,000 -66,966,000 261,655,000 145,598,000 116,057,000 -68,373,000
Dec 2023 58,749,000 -168,244,000 -9,058,000 298,418,000 145,805,000 152,613,000 -78,205,000
Dec 2022 150,018,000 -121,418,000 -119,758,000 280,468,000 138,455,000 142,013,000 -86,959,000

TTM Snapshot

Revenues TTM
$167,674,000
NetIncome TTM
$-14,592,000
OpCashFlow TTM
—
Assets (Latest)
$345,409,000
Forward EPS
$-1.54

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $3.00 · spot: $1.97 · call volume: 1 · put volume: 60

Peers — same industry

TickerNameMarket CapLastDaily %
MSLE Satellos Bioscience Inc. $131.54M $6.20 —
MENS Jyong Biotech Ltd. $133.62M $1.80 —
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $124.92M $4.33 —
SION Sionna Therapeutics, Inc. $138.87M $3.07 —
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —

News headlines (Yahoo Finance, 1h cache)

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:25 · Yahoo
MacroGenics: Q3 Earnings Snapshot
2026-11-12 21:16 · Yahoo
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
2026-11-12 21:01 · Yahoo
MacroGenics to Participate in Upcoming Investor Conferences
2026-11-05 21:05 · Yahoo
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
2026-11-03 21:05 · Yahoo
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
2026-10-26 11:06 · Yahoo
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
2026-10-23 13:15 · Yahoo
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
2026-10-15 20:05 · Yahoo
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
2026-10-09 12:40 · Yahoo
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.